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The role of cyclic AMP (cAMP) in immunologic 
inflammation has received considerable experi-
mental attention although, because of the physical 
and biologic complexity of many of the more 
interesting responses and a relative paucity of 
direct cAMP measurements, a substantial propor-
t ion of the work is difficult to interpret. Despite 
some conflicting evidence. one might generalize in 
regard to these studies by describing cAMP as an 
inhibitor of immunologic inflammation [1). Thus 
cAMP itself. its lipophilic derivatives or hormones, 
and cAMP phosphodiesterase inhibitors which 
raise intracellular cAMP have been reported to 
inhibit: (1) the release of lysosomal enzymes and 
mediators of immediate and delayed hypersensi-
tivity from neutrophils, macrophages, mast cells, 
or lymphocytes, (2) lymphocyte activation byanti· 
gens and lectins, (3) lymphocyte mediated cytol-
ysis, (4) platelet and lymphocyte aggregation, (5) 
neutrophil or macrophage responsiveness to 
chemotactic and phagocytic stimuli. 
Despite the ability of cAMP to modulate all the 
above responses, the potential usefulness of 
methylxanthines, catecholamines. and prosta-
glandins as therapeutic inhibitors of inflammation, 
based on their common ability to increase intracel-
lu lar cAMP, will no doubt depend to a considera-
ble extent on the agent and the tissue in question 
and whether the response is already under way at 
the time the agent is applied. For a variety of 
reasons many tissues fa il to maintain increased 
intracellular levels of cAMP despite continuous 
exposure to appropriate pharmacologic agents [2) 
and one would assume that under these circum-
stances the inflammatory stimulus would eventu-
ally break through. In addition, inasmuch as cAMP 
is apparently involved as a natural modulator of 
immune reactions, it is at least theoretically possi-
ble that pharmacologic manipulation might on 
occasion be detrimental. For example, because it 
increases intracellular cAMP and because in-
creases in cAMP inhibit histamine release, extra-
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cellular histamine may serve as a negative feed -
back inhibitor of further histamine re lease [31. In 
addition, rustamine is capable of increasing cAMP 
in lymphocytes and inhibiting lymphocyte-
mediated cytolysis [41. This effect is of considera-
ble interest since the proportion of lymphocytes 
that are susceptible to modulation by histamine 
appears to increase with time after immunization. 
This may permit histamine to exert differing 
effects on sensitized lymphocytes depending on the 
stage of the response. Alterations of this kind may 
help to explain the ability of the immune appara-
tus to undergo a graded response in which a con-
siderable number of antibodv molecules and sensi-
tized cells are produced d~ring the early phases 
of the response. but in the absence of further stim-
ulat ion by antigen the response eventually dies 
away. 
In addition to the evidence that cAMP can 
inhibit immune responses, it would appear that 
cAMP can play a dual role in lymphocyte re-
sponses to lectins, in antigen-induced proliferation 
of antibody-producing cells. and in chemotactic 
responsiveness to various stimuli. In each of these 
situations stimulation as well as inhibition is seen 
[1.5.6]. In addition. it has recently been shown 
that cAMP acts as a second messenger for thymic 
hormones aiding in the conversion of immature to 
mature T-lymphocytes. Since the possible role of 
cAMP in activation of lymphocytes by lectins has 
been a major interest in our laboratory. our find-
ings in this system will be discussed in some detaiL 
Lymphocytes can be activated to undergo mito-
genesis by a variety of stimuli including suitable 
lectins [phytohemagglutinin (PHA), concanavalin 
A (Con-A) , lentil , fava bean). periodate, antigens 
(in a sensitized individual) , antibodies (with speci-
ficity for determinants on the lymphocyte surface). 
proteolytic enzymes, heavy metals (Zn-;, Hg+- ), 
calcium ionophores, and various bacterial cell wall 
products [7). Lectins have been widely used for 
studies of lymphocyte activation because previous 
sensitization is not a requirement, a high percent-
age of the cells are activated, the stoichiometry of 
lectin binding to the cell surface is easily deter-
mined, and marked similarities exist in t he meta-
bolic changes produced by mitogenic lectins and 
antigens. In addition, there a re other lectins such 
as wheat-germ agglutinin (WGA) and mushroom 
agglutinin (MRA) which interact effectively with 
the lymphocyte surface but fail to produce mito· 
genic stimulation . PHA and Con-A, which are the 
most commonly used mitogenic lectins, produce a 
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wide variety of metabolic changes when they 
interact with lymphocytes. There is evidence that 
lymphocytes must continue to interact with PHA 
or Con- A for at least 8 to 20 hr before the cells are 
irrevocably committed to undergo blast transfor-
mation and divide [8.91, but changes in t ransport. 
membrane phosphatidylinositol turnover, and 
histone phosphorylation and acetylation occur very 
rapidly. Because of the well-known regulatory role 
of cAMP in polypeptide hormone action it seemed 
possible that cAMP might be important in lym-
phocyte activation by lectins. The results of stud-
ies conducted in human peripheral blood lympho-
cytes over the past 6 years in our laboratory in 
regard to the possible impor tance of cAMP in PHA 
and Con-A stimulation can be summarized as 
follows: 
1. Lymphocytes undergo small (1.5- to 3.0-fold) 
but consistent increases in whole-cell cAMP be-
ginning as early as 60 sec after exposure to lectin. 
The reaction reaches a maximum after 5 to 1.5 min 
(10). The response occurs over a broad dose range. 
including optimal mitogenic concentrations, and is 
seen in highly purified T-Iymphocytes as well as 
T-cell- B-cell mixtures [11). 
2. Both PHA and Con-A activate adenylate 
cyclase in lymphocyte homogenates [10 J, purified 
lymphocytes, and lymphocyte plasma membranes, 
although the effect is small relative to that of 
fluoride and prostaglandin E, (PGE,). Since PGE , 
produces a much larger cAMP response in intact 
lymphocytes than the two lectins do, the difference 
in magnitude of the adenylate cyclase responses is 
probably not surprising. 
3. The increase in cAMP in response to Con-A is 
specifically blocked or reversed by low (I mM) 
concentrations of a -methyl mannoside and a -
methyl glucoside and is induced by Con-A 
attached to Sepharose. indicating that it takes 
place through specific carbohydrate receptors on 
the cell surface 112J. In addition. cAMP accumula-
tion in this location can be further shown by an 
immunofluorocytochemical procedure in which the 
intracellular distribution of cAMP is dete rmined 
by virtue of its abilit.y to interact with anti-cAMP 
antibody [13J. Presumably the cAMP that is being 
detected using this procedure is in a protein-bound 
form . 
4. Graded quantities of cAMP and dibutYTyl 
cAMP produce modest sti mulation of lymphocyte 
mitogenesis although the effect is much smaller 
than that of the mitogenic lectins themselves [14, 
15]. At higher concentrations cAMP itself and 
PGE" isoproterenol, and theophylline all inhibit 
the mitogenic response to PHA. With the excep-
tion of protein phosphorylation (see below) early 
metabolic responses to PHA such as Ca-- and 
aminoisobutyric acid (ALB) uptake and phos-
phatidylinositol turnover are reproduced poorly or 
not at all by cAMP a lthough there is some evidence 
that nuclear histone phosphorylation can be stimu-
lated [16J. 
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5. Lymphocytes preincubated with " p. - and 
exposed to PHA or Con-A incorporate increased 
amounts of "P into high-molecular-weight pro-
teins as determined by sodium dodecyl sulfate 
(SDS) polyacrylamide gel electrophoresis [17.18]. 
A similar effect is produced by N.-monobutyryl 
cAMP, strongly suggesting that the phosphoryla-
tion is cAMP dependent. Other lymphocyte mito-
gens (tryp in. periodate. the calcium ionophore 
A23187) also are stimulator~' (unpublished data). 
Interestingly, PGE" isoproterenol. and theophyl· 
line, which increase whole-cell cAMP levels, do not 
stimulate protein phosphorylation in the same way 
that PHA and Con-A do, suggesting the lym-
phocyte may contain different functional pools of 
cAMP. In addition, preliminary evidence has been 
obtained for an endogenous, cAMP-dependent pro-
tein kinase in purified lymphocyte plasma mem-
branes (unpublished data). 
The most interesting observation we have made 
has been in regard to the effects of two nonmito-
genic lectins, WGA and MRA, and latex particles 
in these systems. All three agents produce rapid 
increases in lymphocyte cAMP but fail to stimu-
late mitogenesis or early parameters of lymphocyte 
activation such as AlB uptake and phosphatidyl 
inositol (PI) turnover [19.20]. Moreover. depend-
ing on the agent. most or all of these responses are 
actually inhibited . indicating that the reagents are 
effectively interacting with the cell sur face. inhibi-
tion is seen both in the presence and absence of 
mitogenic lectins and does not appear to be due to 
changes in cell \'iabilit~. ~or is it due to some other 
form of nonspecific toxicity since the effect is 
blocked by appropriate monosaccharides. The 
basis for the inhibition and its significance in terms 
of cAM P action during lymphocyte activation is 
not altogether clear. The fact that agents which 
interact with the lymphocyt.e surface and increase 
cAMP can either promote or inhibit lymphocytes 
would seem. at least on superficial analysis. to 
argue against a modulatory role of cAMP in the 
response. On the other hand. in parallel studies of 
protein phosphorylation. WGA and latex inhibit 
the response whereas PHA and Con-A are stimula-
tory (unpublished data). Since competitive bind-
ing and capping studies suggest that WGA and 
Con-A attach to different receptors on the lym-
phocyte surface (unpublished data). we would 
suggest that Con-A and WGA are interacting with 
microanatomatically and functionally distinct 
areas of the lymphocyte plasma membrane, ex-
plaining their opposing effects on protein phospho-
rylation and lymphocyte activation. The hypothe-
sis requires that cAMP be compartmentalized in 
the lymphocyte pia rna membrane, as already 
suggested above. Obviously this is an elaborate 
and controversial concept of cAMP action and 
considerable additional validation is needed. 
The demonstration that lymphocytes contain 
discrete receptors with either positive or negative 
modulatory effects on lymphocyte growth and 
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differentiation may have broad implications for 
cell biology as a whole . Negative modulatory sites 
analogous to the ones perturbed by WGA and 
related agents may well be involved in the poorly 
understood phenomenon of immunologic tolerance 
or in negative regulatory effects of Iymphokines 
and supporessor T-cells on lymphocyte growth. Of 
even greater importance. loss of a negative regula-
tory site can be suspect.ed as a possible mechanism 
by which cells might lose their susceptivity to 
contact inhibition and escape their normal 
restraints to growth. In this connection it is of 
interest that cAMP is increased when untrans-
formed cells undergo contact inhibition whereas 
transformed cells fail to show increases in cAMP 
and continue to grow 121.22 1. In addition. a 
number of malignant cell lines more readily 
undergo clustering of their WGA recept.or sites, 
explaining their enhanced susceptibility t o aggluti-
nation by this lectin [23.24]. l"ot inconceivabl~·. a 
clustered site is also a functionally inadequate site 
or the clustering itself implies that WGA is 
anchored ineffectively to underlying structures in 
or near the mem brane, even before the rearrange-
ment of receptors takes place (unpublished datal. 
If either argument is valid it. may be possible to 
show t hat other untransformed cells respond to 
WGA in much the same way lymphocytes do both 
with increases in cAMP and inhibition of cellular 
transport and metabolism whereas transformed 
cells are no longer susceptible to the lectin. This 
scheme may not apply to every cell since in rat fat 
cells vYGA appears to inhibit adenylate cyclase and 
stimulate glucose transport [25]. But even in the 
fat cell system , one would presume that if the 
cyclase to which WGA is linked were stimulated by 
an appropriate agent, inhibition of glucose trans-
port would be the result. 
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